Spots Global Cancer Trial Database for Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

Official Title: A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design

Study ID: NCT04522544

Conditions

Hepatocellular Carcinoma Non-resectable

HCC

Interventions

Study Description

Brief Summary: A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with either Y-90 SIRT or DEB-TACE for intermediate stage HCC with pick-the-winner design

Detailed Description: The IMMUWIN phase II will test the safety and anti-tumor efficacy of the combination of Durvalumab and Tremelimumab with either Y-90 SIRT or DEB-TACE. Patients will be randomized into two experimental arms, one receiving SIRT + Durvalumab + Tremelimumab, the other arm receiving TACE + Durvalumab + Tremelimumab. It will be determined whether the combination of immunotherapy with SIRT or TACE is more promising.